Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) ...
By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient ...
This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results